Real-world Assessment of 2879 COVID-19 Patients Treated With Monoclonal Antibody Therapy: A Propensity Score–Matched Cohort Study

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread globally and cause significant morbidity and mortality. Antispike protein monoclonal antibody (mAb) therapy has been shown to prevent progression to severe coronavirus disease 2019 (COVID-19). The objective...

Descripción completa

Detalles Bibliográficos
Autores principales: Cooper, Megan H, Christensen, Paul A, Salazar, Eric, Perez, Katherine K, Graviss, Edward A, Nguyen, Duc, Musser, James M, Huang, Howard J, Liebl, Michael G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088516/
https://www.ncbi.nlm.nih.gov/pubmed/35559124
http://dx.doi.org/10.1093/ofid/ofab512

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9088516/
https://www.ncbi.nlm.nih.gov/pubmed/35559124
http://dx.doi.org/10.1093/ofid/ofab512

Ejemplares similares